April 27, 2020 / 11:06 AM / a month ago

BRIEF-Phase 3 Trial Of Libtayo® As Monotherapy For First-Line Advanced Non-Small Cell Lung Cancer Stopped Early Due To Improvement In Overall Survival

April 27 (Reuters) - Regeneron Pharmaceuticals Inc:

* PHASE 3 TRIAL OF LIBTAYO® (CEMIPLIMAB) AS MONOTHERAPY FOR FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER STOPPED EARLY DUE TO HIGHLY SIGNIFICANT IMPROVEMENT IN OVERALL SURVIVAL

* REGENERON PHARMACEUTICALS INC - LIBTAYO DECREASED RISK OF DEATH BY 32.4% COMPARED TO CHEMOTHERAPY

* REGENERON PHARMACEUTICALS INC - TRIAL WILL BE MODIFIED TO ALLOW ALL PATIENTS TO RECEIVE LIBTAYO FOR INVESTIGATIONAL USE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below